Eli Lilly and Company (LLY) Next Earnings Date & Options-Implied ±6.8% Move
$1,373.70 +6.63% NYSE • Public Delayed / 60s Snapshot
Eli Lilly and Company (LLY) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (84% profit margin, 32% return on capital) with steady institutional support. Even if the broader market gets choppy, the company’s underlying cash engine and big-money support put the odds in buyers’ favor.
ROARABLE B • BUY
Cap $1.33T
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERBUY • B
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw B+ · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE+23% Base Target
WHALE OPTIONS TUG-OF-WAR:45% Call Buyers ($5.4M)
55% PutsMax Pain: $1,200.00
NEXT EST. REPORT: Jan 28, 2027 (~87 DAYS)
±$93.41 Expected SwingOptions-Implied Post-Earnings ±6.8% Bell Curve
TRADER CROWD SENTIMENT POLL
Will LLY Beat & Rip or Miss Next Quarter?
Trailing EPS: $30.81 • YoY Revenue Growth: 45.5%
55% Bullish Beat45% Bearish Miss
Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence
| Period | Filed | Revenue | Net Profit | Free Cash Flow | Gross Margin |
|---|---|---|---|---|---|
| Q3 2026 | 2026-10-29 | $24.40B | $6.45B | $11.40B | 83.9% |
| Q2 2026 | 2026-08-05 | $22.97B | $7.09B | $10.69B | 85.8% |
| Q1 2026 | 2026-04-30 | $19.80B | $7.40B | $5.33B | 81.9% |
| Q4 2025 | 2026-02-12 | $19.29B | $6.64B | $3.23B | 82.5% |
| Q3 2025 | 2026-10-29 | $17.60B | $5.58B | $8.84B | 82.9% |
| Q2 2025 | 2026-08-05 | $15.56B | $5.66B | $3.09B | 84.3% |
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher + Guest Options & Prop-Trading Strategist
Whale Flow & Momentum Playbook: Trading LLY & AI Leaders Without Chasing Tops
- ✓Exact institutional whale strikes & implied earnings range on LLY this week
- ✓How active traders scale setups using funded prop-firm accounts instead of risking savings
- ✓Free bonus: instant RQD Rating Flip alerts on all tracked momentum leaders
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
LLY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +47.15%▲ RESISTANCE BREAKOUT
2026-10-30O $1,286.4H $1,449.7L $1,260.3C $1,417.5VOL 15.63M
RES: $1,364.7SMA50: $1,197.1SMA200: $1,091.2
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
LLY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
-0.53% YoY Shares
SEC XBRL FY2024 → FY2025: Net share cannibal / buyback tailwind.
Reverse-DCF Expectations Hurdle (#30)
35.5%/yr Implied 5Y Growth
vs. +45.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
DEVELOPING · Incretin Capacity Base Reclaim
Trigger: $1452.98 • Invalidation: $1349.50
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
WST → LLY Confirmed Filing
West Pharmaceutical Services manufactures NovaPure fluoropolymer-coated elastomer plungers and cartridge seals required inside sterile single-dose and multi-dose GLP-1 auto-injector pens.
TMO → LLY Confirmed Filing
Following Novo Holdings acquisition of Catalent fill-finish sites, Eli Lilly and rival GLP-1 developers increasingly rely on Thermo Fisher Patheon sterile fill-finish lines to clear injectable pen bottlenecks.
LLY → NVO Confirmed Filing
Eli Lilly dual GIP/GLP-1 agonist tirzepatide (Zepbound/Mounjaro) demonstrated superior head-to-head weight loss vs. Novo Nordisk semaglutide (Wegovy) in SURMOUNT-5, intensifying PBM rebate competition.
AI Analyst Theses, Washington Policy & Company Video
💡 Friday Evidence Audit: What Confirmed, What Stalled & Where Options Overpriced the Move (felix-orven)
💡 Starter Kit: Cash-Fortress Zero-Dilution Compounders (ellis-vennor)
🏛️ COMMENT_RULEMAKING: CMS Contract Year Medicare Advantage Capitation Benchmark & Part D GLP-1 Coverage Rulemaking (Centers for Medicare & Medicaid Services (HHS — 42 CFR Parts 422 & 423))
🎬 No recent verified company-specific video clip queued for LLY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
LLY Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhen is LLY's next earnings date?
Based on SEC filing cadence, Eli Lilly and Company (LLY)'s next quarterly earnings window is estimated around Jan 28, 2027.
How much is LLY stock expected to move on earnings?
Options markets currently imply a ±6.8% post-earnings move for LLY, projecting a trading range between $1280.29 and $1467.11.